Sergey Badalyan, Publishing Editor at OncoDaily, shared a post on LinkedIn:
“Currently attending the ‘Recent Developments in Thoracic Oncology (From Practice to Design)‘ conference at Yerevan State Medical University named after Mkhitar Heratsi.
Right now, we are hearing from Dr. Gregory Kalemkerian, Professor of Internal Medicine at the University of Michigan and a renowned expert in thoracic oncology, who chairs the National Comprehensive Cancer Network (NCCN) Small Cell Lung Cancer Guidelines Panel.
He is sharing his perspective on Stage III NSCLC management, covering safe treatment options like Cisplatin/Pemetrexed with RT, and highlighting key results from landmark trials such as PROCLAIM, PACIFIC, and LAURA (EGFR+, with consolidation osimertinib).
Moderators: Armen Mkhitaryan, Sergo Mkhitaryan.
An invaluable opportunity to follow expert opinion, such as Dr Kalemkeryan’s, firsthand here in Yerevan.”
More posts featuring Gregory Kalemkerian on OncoDaily.
